This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Sculpher M, Palmer S. After 20 years of using economic evaluation, should NICE be considered a methods innovator? Pharmacoeconomics. 2020. https://doi.org/10.1007/s40273-019-00882-6.
National Institute for Health and Care Excellence. Changes we are making to health technology evaluation; 2020. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation. Accessed 17 Jan 2020.
National Institute for Health and Care Excellence. The principles that guide the development of NICE guidance and standards. In: National Institute for Health and Care Excellence Public Board Meeting, 20 November 2019. https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Public-board-meetings/agenda-and-papers-nov-19.pdf. Accessed 17 Jan 2020.
NHS England. The Accelerated Access Collaborative; 2020. https://www.england.nhs.uk/ourwork/innovation/accel-access/. Accessed 17 Jan 2020.
NHS England. The Commercial Framework for Medicines; 2020. https://www.engage.england.nhs.uk/consultation/nhs-commercial-framework-for-medicines/. Accessed 17 Jan 2020.
National Institute for Health and Care Excellence. Review of methods for health technology evaluation programmes. In: National Institute for Health and Care Excellence Public Board Meeting, 17 July 2019. https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Public-board-meetings/agenda-and-papers-july-19.pdf. Accessed 17 Jan 2020.
The authors are grateful for the comments and suggestions made by Mirella Marlow, Rebecca Smith and Helen Knight at NICE.
Conflict of interest
The authors are employed by the National Institute for Health and Care Excellence; MB is a member of the NICE methods review steering group, and IW is a member of the NICE methods review steering and working groups. MB is on the Board of Directors for the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). No specific funding was used for work detailed in this paper.
About this article
Cite this article
Boysen, M., Watson, I. Reflections on NICE’s Uptake of New Methods: Past, Present, and the 2020 Review. PharmacoEconomics 38, 243–245 (2020). https://doi.org/10.1007/s40273-020-00888-5